Commentary

iMedPub Journals
www.imedpub.com

Journal of Renal Medicine

2024
Vol.7 No.5:44

Navigating Treatment Options for Rare Subtypes of Renal Cell Carcinoma

Chang Kang*

Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea

Corresponding author: Chang Kang, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, E-mail: kangc@outlook.com

Received date: August 19, 2024, Manuscript No. IPJRM-24-19791; **Editor assigned date:** August 22, 2024, PreQC No. IPJRM-24-19791 (PQ); **Reviewed date:** September 05, 2024, QC No. IPJRM-24-19791; **Revised date:** September 12, 2024, Manuscript No. IPJRM-24-19791 (R); **Published date:** September 19, 2024, DOI: 10.36648/ipjrm.7.5.44

Citation: Kang C (2024) Navigating Treatment Options for Rare Subtypes of Renal Cell Carcinoma. J Ren Med Vol.7 No.5: 44.

Description

Renal Cell Carcinoma (RCC) is a heterogeneous group of tumors arising from the renal epithelium, with clear cell carcinoma being the most common subtype. However, rarer subtypes, such as papillary, chromophobe and collecting duct carcinoma, present unique challenges in diagnosis and treatment. Understanding these subtypes is important for personalized treatment approaches, as they exhibit different biological behaviors and responses to therapies. This article will discuss the characteristics, treatment options and clinical considerations for rare subtypes of RCC. Navigating the treatment landscape for rare subtypes of renal cell carcinoma presents unique challenges, but advances in research and targeted therapies are prepare for improved outcomes. As our understanding of these tumors deepens, the importance of personalized medicine becomes increasingly clear. Patients diagnosed with rare subtypes of RCC should be empowered to discuss all available treatment options, including the potential benefits of participating in clinical trials, to ensure they receive the greatest attention according to their own requirements.

Rare subtypes of RCC

Papillary Renal Cell Carcinoma (PRCC) comprising about 10%-15% of all RCC cases, PRCC can be further divided into type 1 (less aggressive) and type 2 (more aggressive). Type 1 is often linked to a more favorable outcome. Mutations in the MET gene are common in type 1, while type 2 often involves mutations in the Fumarate Hydratase (FH) gene. Common symptoms include hematuria, flank pain and weight loss. Chromophobe renal cell carcinoma accounting for about 5% of RCC cases, chromophobe carcinoma generally has a better prognosis than clear cell and papillary subtypes. It often presents at an earlier stage and is less aggressive. Often occurring genetic changes include the deletion of chromosomes 10 and 1. Symptoms are similar to other RCC subtypes but may also include hypercalcemia. >1% of instances with RCC are Collecting duct carcinoma, an uncommon and severe type of the disease. This subtype originates from the collecting ducts and has a poor prognosis.

Often associated with mutations in the *SMARCB1* gene, leading to aggressive disease. Patients often present with advanced disease, experiencing severe flank pain and hematuria. This category surround tumors that do not fit neatly into established subtypes. They may present with mixed histological features and unpredictable behaviors.

Treatment options for rare subtypes

The primary treatment for localized RCC is radical nephrectomy, which involves the removal of the affected kidney and surrounding tissue. Partial nephrectomy may be considered for smaller tumors or when preserving kidney function is essential. For patients who are not surgical candidates or have small tumors, ablative techniques such as Radiofrequency Ablation (RFA) or cryoablation may be options. The advent of targeted therapies has changed the landscape of RCC treatment. Agents such as sunitinib and pazopanib are typically used for clear cell RCC but may be effective in certain cases of PRCC. Studies suggest that MET inhibitors may be particularly beneficial for patients with type 1 PRCC. Immune checkpoint inhibitors like nivolumab and pembrolizumab have shown in treating advanced RCC, including some rare subtypes. However, response rates can vary significantly. Researchers are study the combinations of targeted therapies and immunotherapy to enhance efficacy, particularly in rarer subtypes with aggressive behavior. Given the limited treatment options for rare RCC subtypes, clinical trials are important for advancing knowledge and developing new therapies. Patients should be encouraged to consider participating in trials that focus on their specific subtype. Accurate diagnosis is paramount, as treatment options can vary widely between subtypes. Biomarkers and genetic profiling may assist in distinguishing between subtypes and guiding therapy. Due to their rarity, there is often limited clinical data on the efficacy of treatments for these subtypes. This makes it difficult to establish standardized treatment protocols. Managing rare subtypes of RCC often requires a multidisciplinary team, including urologists, oncologists, radiologists and pathologists. Collaboration is essential for developing individualized treatment plans.